Navigation Links
Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
Date:4/21/2009

OXFORD, England, April 21 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced today that it has initiated a phase II clinical study of its ToleroMune(R) technology in allergy patients with asthma. The trial builds on positive phase II results that demonstrated the potential clinical benefits of ToleroMune allergy therapy, and extends clinical investigations to those with allergy-associated asthma.

The lastest study, which is underway in Canada, will enrol 48 patients with confirmed cat allergies and cat-allergen induced asthma. The randomised, double-blind, placebo-controlled trial will study the use of a standard dose of ToleroMune administered over a number of weeks. This is in marked contrast to most current immunotherapy treatments, which require carefully escalated weekly dosing over many months, followed by further monthly doses for several years, to reduce the risk of potentially serious adverse reactions. During the study, each patient will receive a controlled 'challenge' with cat allergens, both before and after treatment, to allow investigators to assess the effect of ToleroMune therapy compared to placebo.

"This study marks an important milestone in the development of our ToleroMune anti-allergy technology, as it extends our target patient group to those with more serious allergies that can result in asthma attacks," said Steve Harris, Circassia's CEO. "We believe that Circassia's allergy therapies will offer patients important clinical benefits. Most existing treatments address either symptoms only, or require lengthy and complicated dosing because of their potential to lead to serious and even lifethreatening reactions. In contrast, our clinical results show that ToleroMune has the potential to treat the underlying causes of allergies, using short and simple courses of treatment that minimize the risk of severe side effects."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's anti-allergy products offer potential major clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the market for current treatments is approximately $12 billion per year. The prevalence of cat allergies is also high, with 1-in-6 Americans and nearly 10% of Europeans suffering from the condition.

ToleroMune technology has additional potential regulatory and supply benefits for Circassia. Its state-of-the-art manufacturing fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and eliminating the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments.

Circassia has a highly experienced management team with a proven track record in product development and commercialization. Having successfully completed two fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

    For more information please visithttp://www.circassia.co.uk.

    Contacts

    Steve Harris                 Rob Budge
    CEO                          RJB Communications
    Circassia Tel:                       +44-(0)1865-760969
    Tel: +44-(0)1865-784574      Mobile: +44-(0)7710-741241


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
2. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
3. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
4. American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast
5. Study Says Allergy Shots Help Children, Reduce Health Care Costs
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects
8. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
9. Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth
10. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. ... ... ... ... Astellas is a ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
Breaking Medicine News(10 mins):